Boston Biomedical Officers and Directors
Boston Biomedical is a subsidiary of Sumitomo Dainippon Pharma Co., Ltd., which is traded on the Tokyo Stock Exchange. Its Board of Directors can be found at http://www.ds-pharma.com/profile/executive/directors.html.
Boston Biomedical’s Board of Directors includes executive leadership of Sumitomo Dainippon Pharma Co., Ltd., and an external board member, William J. Rutter, PhD.
Chiang J. Li, MDFounder, President, CEO, and Chief Medical Officer, Boston Biomedical, Inc.
Executive Officer, Head of Global Oncology for Sumitomo Dainippon Pharma Group
Dr. Li is a physician, scientist, inventor, entrepreneur, and seasoned corporate executive with internationally recognized accomplishments in therapeutic science and medical innovation. Dr. Li has founded multiple successful biotech startups that have collectively created hundreds of R&D jobs as well as several billions of dollars in valuation. He founded Boston Biomedical in 2006 with a team of 2 dozen researchers laid off from a prior employer, and has served as its President and CEO since its inception. Under his leadership, Boston Biomedical has grown to become an organization with more than 120 oncology product R&D researchers, a seasoned business management infrastructure, and a world-leading product pipeline designed to target cancer cell stemness and other promising avenues of oncology research. In 2013, Boston Biomedical was selected as the sole recipient of the special award “Company to Watch” by the 10th Massachusetts Economic Impact Award Committee.
Dr. Li has performed biomedical research for more than 20 years and has more than 50 publications in leading biomedical journals, including numerous highly cited articles. He is a named inventor in more than 230 patents or patent applications worldwide, including a number of first-in-class cancer therapeutics, an award-winning platform technology for designing gene-targeted therapeutics, and one of the world’s first synthetic biology therapeutics.
Dr. Li has more than 15 years of patient care and clinical development experience in academia and industry, and has led efforts to translate a number of his inventions from bench to bedside for patients with life-threatening disorders. He has been a chief executive in charge of product R&D in public and private biotech companies for more than a decade, including drug discovery, preclinical development, clinical development, pharmaceutical development and manufacture, regulatory affairs, and intellectual property.
Dr. Li and his work have received a number of awards/recognitions with more recent examples including his election as Fellow of the US National Academy of Inventors, direct election as Fellow of the American College of Physicians (invited direct election is considered a singular honor), North American Technology Innovation of the Year (2010, Frost & Sullivan), GRL Award in biotechnology (Korea), Distinguished Foreign Professor (Dongguk University, Korea), Honoree for outstanding achievement (Massachusetts Asian American Commission), Life Time Achievement Award (CAST-USA), and Massachusetts Immigrant Entrepreneur Award (sole recipient for Science Business, 2013). He is also a member of the Overseas Experts Advisory Committee (China State Council, Office of Foreign Affairs), and serves on the Board of Trustees at Beth Israel Deaconess Medical Center of Harvard Medical School.
Dr. Li graduated from the Harvard-MIT Division of Health Science and Technology, received his MD magna cum laude from Harvard University, and completed residency and fellowships at Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center. He has also received executive education at Harvard Business School.
Kazuo Koshiya, PhDPresident, Boston Biomedical Pharma, Inc.
Senior Executive Officer, Head of Global Oncology Office, Sumitomo Dainippon Pharma Co., Ltd.
Patricia S. AndrewsExecutive Vice President and Chief Operating Officer, Boston Biomedical Pharma, Inc.
Ms. Andrews joined Boston Biomedical Pharma, Inc. in 2013, and is responsible for all aspects of commercial operations and Medical Affairs.
Ms. Andrews served as Executive Vice President and Chief Commercial Officer at Incyte Corporation, a US-based biopharmaceutical company focused on building a portfolio of proprietary small-molecule drugs for oncology and inflammation. Under her leadership, Incyte was transformed from a solely R&D organization into a successful commercial enterprise with the launch of its first product, which was also first-in-class and first-in-disease. She established the commercial organization and led all functions within sales and marketing. She was also responsible for business development and completed multiple significant product licensing deals for Incyte, including one of the largest licensing deals in biotech in 2009.
Prior to Incyte, Ms. Andrews spent 17 years at Pfizer, culminating in her role as Vice President and General Manager of the US Oncology Business Unit, a $900 million portfolio of products in colorectal cancer, breast cancer, and renal cell carcinoma. Ms. Andrews received her MBA from the University of Michigan and a BA from Brown University.
Board of Directors
William J. Rutter, PhDMember, Boston Biomedical Board of Directors
CEO and Founder, Synergenics, LLC
Dr. Rutter is Chairman and Founder of Synergenics, LLC, which owns and controls a portfolio of biotechnology companies at various stages of development.
In his academic career, Dr. Rutter joined the University of California–San Francisco (UCSF) as head of the newly formed department of Biochemistry and Biophysics in 1968, and played a key role in developing UCSF into a major scientific institution. In research, he is particularly known for the discovery of the enzymes involved in the expression of DNA (RNA polymerases), the first cloning of the insulin gene, the cloning of hepatitis B virus (HBV), and formation of an HBV-like particle that provided the basis for a safe and protective vaccine.
With 2 colleagues, Dr. Rutter founded Chiron in 1981, a pioneering biotech firm that developed the first recombinant vaccine (against HBV) with Merck and a process for manufacturing insulin from yeast with Novo-Nordisk. Chiron was the first to clone the AIDS (HIV) virus and to discover, clone, and sequence the hepatitis C virus (HCV). Chiron developed quantitative diagnostic tests for HIV, HBV, and HCV, thus providing the means for eliminating blood contaminated with these viruses, a major contribution to public health worldwide. Chiron developed and promulgated the concept of “viral load” as the basis for determining disease status, as well as the basis for developing and evaluating antivirals and other treatment protocols for these and other diseases.
Prior to Chiron, Dr. Rutter was a consultant to Abbott Laboratories for about 20 years, and a member of the Amgen Scientific Advisory Board. Dr. Rutter’s past board memberships include Novartis, Sangamo Biosciences, Cytokinetics, Nugen, Oscient Pharmaceuticals, and Epitomics.
Dr. Rutter also currently serves on the boards of Eureka Genomics, Apexigen, One Globe, and Cellworks. He is Chairman of the Synergenics companies: Synco Biopartners, ReLIA Diagnostic Systems, Numera Health, Ventria Bioscience, Humabs Biomed, Pathologica, and BioEnergenix.
Dr. Rutter is a member of the National Academy of Sciences and the American Academy of Arts and Sciences, and has received numerous awards for his contributions to science and the biotechnology industry.